Spectrum Sees Potential Path For Poziotinib In NSCLC Despite Expected CRL

 
• By Alaric DeArment
  
The FDA sent a complete response letter to Spectrum for poziotinib in NSCLC • Source: Shutterstock

More from New Products

More from Scrip